THOMAS G. RICKS - 10 Jun 2022 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role
Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
SNSE
Transactions as of
10 Jun 2022
Net transactions value
$0
Form type
4
Filing time
14 Jun 2022, 16:15:29 UTC
Previous filing
08 Jun 2022
Next filing
05 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNSE Common Stock Award $0 +4,466 $0.000000 4,466 10 Jun 2022 Direct F1
holding SNSE Common Stock 334,931 10 Jun 2022 By Ricks Family Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNSE Stock Option (Right to Buy) Award $0 +14,550 $0.000000 14,550 10 Jun 2022 Common Stock 14,550 $2.05 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer through such vesting date.
F2 These shares are held by the Ricks Family Trust. Thomas Ricks is a trustee of the Ricks Family Trust and, accordingly, may be deemed to have voting and dispositive power with respect to the shares held by Ricks Family Trust.
F3 The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.